Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ainos Inc (NQ: AIMD )

0.4550 -0.0130 (-2.78%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 39,424
Open 0.4610
Bid (Size) 0.4203 (13)
Ask (Size) 0.4376 (4)
Prev. Close 0.4680
Today's Range 0.4400 - 0.4680
52wk Range 0.4010 - 4.290
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ainos Expands Patent Portfolio With Strategic Shareholder’s Cutting-Edge Technology Assets
Via ACCESSWIRE
Ainos Highlights VELDONA Clinical Advancements and Market Potential in Water Tower Research Spotlight Podcast
Via ACCESSWIRE

Performance

YTD
-76.30%
-76.30%
1 Month
-15.74%
-15.74%
3 Month
-14.15%
-14.15%
6 Month
-57.08%
-57.08%
1 Year
-84.71%
-84.71%

More News

Read More
Ainos Advances Healthcare and Industrial Innovations with AI Nose and VELDONA Technologies
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Ainos, Inc. Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial, Highlighting Value of FDA-Designated Orphan Drug VELDONA
Via ACCESSWIRE
Ainos Spotlighted in Water Tower Research Report on VELDONA Clinical Study for Sjogren’s Syndrome
Via ACCESSWIRE
Ainos to Participate in H.C. Wainwright 26th Annual Global Investment Conference
Via ACCESSWIRE
Ainos CEO Highlights AI Nose Achievements and Upcoming 2H 2024 Milestones in Shareholder Letter
Via ACCESSWIRE
AIMD Stock Earnings: Ainos Reported Results for Q2 2024
Via InvestorPlace
Ainos Announced Plan to Initiate Taiwan Clinical Study of VELDONA for Treating Sjögren's Syndrome, a Rare Disease With Limited Treatment Options
Via ACCESSWIRE
Water Tower Research Highlights Ainos VELDONA Clinical Trial for HIV+ Patients with Oral Warts
Via ACCESSWIRE
Ainos Announced Plan to Initiate Taiwan Clinical Study for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA
Via ACCESSWIRE
Ainos Secures Taiwan Invention Patent and Advances Global Patent Protection for VELDONA, a Breakthrough in Coronavirus Treatment and Prevention
Via ACCESSWIRE
Ainos Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing Safety
Via ACCESSWIRE
Why Is Ainos (AIMD) Stock Up 38% Today?
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
Ainos Concludes Growth Financing From Lind Partners
Via ACCESSWIRE
Ainos Reports Second Quarter 2024 Financial Results
Via ACCESSWIRE
Ainos Enrolls First Subject for Clinical Study of VELDONA-Based Animal FCGS Drug
Via ACCESSWIRE
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Ainos to Participate in Fireside Chat with Water Tower Research on August 22, 2024
Via ACCESSWIRE
Ainos Secures Exclusive Multi-Regions Invention Patent Licenses from Strategic Partner to Bolster AI Nose and Point-Of-Care Testing
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Ainos Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.